Compare Ginkgo Bioworks Holdings Inc (DNA) vs Vanguard Total Stock Market Index Fund ETF (VTI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Vanguard Total Stock Market Index Fund ETF — how do they compare? Ginkgo Bioworks Holdings Inc trades at $12.95 (market cap $763.64M), while Vanguard Total Stock Market Index Fund ETF trades at $381.93 (market cap $2.30T). The key difference: Vanguard Total Stock Market Index Fund ETF is far larger — about 3011.9× Ginkgo Bioworks Holdings Inc's market cap, and Vanguard Total Stock Market Index Fund ETF is trading nearer its 52-week high, Ginkgo Bioworks Holdings Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and Vanguard Total Stock Market Index Fund ETF for 131 Days on average.
| DNA | VTI | |
|---|---|---|
Market Cap | $763.64M | $2.30T |
Volume | 3,204,177 | 2,982,924 |
Sector | Health | — |
52-Week High | $15.83 | $384.30 |
52-Week Low | $5.48 | $311.68 |
Typical Hold Time | 7 Days | 131 Days |
Enterprise Value | $865.59M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $13.04, up 13.69% in the last session, with a bullish technical signal from moving averages. The company maintains strong gross margins at 68.04% but faces significant losses with a -219.6% net income margin. Recent developments include a $17.5M ARPA-H subcontract for RNA medicine manufacturing and partnerships expanding genetic testing distribution.
While technical momentum appears positive, fundamental challenges persist with substantial cash burn and declining revenue projections. Analyst sentiment is divided equally between buy, hold, and sell ratings. Investment opportunity lies in the company's strategic partnerships and government contracts, balanced against ongoing profitability concerns and competitive pressures in biotech.
VTI trades at $381.82, up 0.21% today, with a bullish technical signal from moving averages and neutral oscillators. The ETF shows strong institutional interest and broad diversification across the U.S. stock market. Recent news highlights its long-term growth potential and cost efficiency, with a dividend scheduled for September 2026.
The outlook for VTI remains positive due to its low-cost structure and exposure to the entire U.S. equity market. Risks include concentration in top holdings and market volatility, but its historical performance supports a solid foundation for long-term investors seeking diversified growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Vanguard Total Stock Market Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the index, which represents approximately 100% of the investable US stock market and includes large-, mid-, small-, and micro-cap stocks. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the full index in terms of key characteristics.
Read more on VTI →
